Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J. Stone, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journalLetterpeer-review

12 Citations (Scopus)
Original languageEnglish
Pages (from-to)410-412
Number of pages3
Issue number3
Publication statusPublished - 15 Jan 2019
Externally publishedYes


  • cholesterol
  • clinical trial

Cite this